


The burden of antimicrobial resistance (AMR) in Qatar

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **40 lives** have been lost each year since 1990 in Qatar due to AMR.
- In 2021, there were an estimated **56 UI (40-72)** deaths attributable to AMR and **222 UI (159-285)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **50 to 69** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Staphylococcus aureus* resistant to methicillin, *Pseudomonas aeruginosa* resistant to carbapenems and *Acinetobacter baumannii* resistant to carbapenems.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Qatar, a 10% reduction means to decrease the number of deaths associated with AMR to **209**, but currently the trend for this country could reach up to **594 UI [417-812]** AMR-associated deaths in 2030.

AMR in Qatar

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Qatar between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Qatar** in 2021, there were an estimated **56 UI (40-72)** deaths attributable to AMR and **222 UI (159-285)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Qatar has the 48th lowest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

	Overall susceptible and resistant	Associated	Attributable
Burden rank	Staphylococcus aureus 84 UI (64-103) ↑	Staphylococcus aureus 55 UI (37-72) ↑	Staphylococcus aureus 17 UI (12-22) ↑
	Escherichia coli 45 UI (35-56) ↑	Escherichia coli 39 UI (29-49) ↑	Acinetobacter baumannii 9 UI (7-11) ↑
	Pseudomonas aeruginosa 37 UI (28-45) ↑	Acinetobacter baumannii 24 UI (17-30) ↑	Escherichia coli 8 UI (6-11) ↑
	Streptococcus pneumoniae 32 UI (25-40) ↑	Streptococcus pneumoniae 23 UI (16-29) ↑	Pseudomonas aeruginosa 6 UI (3-8) ↑
	Klebsiella pneumoniae 29 UI (22-36) ↑	Pseudomonas aeruginosa 20 UI (14-27) ↑	Klebsiella pneumoniae 5 UI (4-7) ↑
	Acinetobacter baumannii 29 UI (22-36) ↑	Klebsiella pneumoniae 20 UI (15-26) ↑	Streptococcus pneumoniae 4 UI (2-5) ↓
	Mycobacterium tuberculosis 24 UI (16-32) ↑	Enterococcus faecium 10 UI (7-13) ↑	Enterococcus faecium 2 UI (1-3) ↑
	Group A Streptococcus 16 UI (12-20) ↑	Proteus spp. 5 UI (3-7) ↑	Enterobacter spp. 1 UI (1-1) ↑
	Enterococcus faecium 12 UI (9-15) ↑	Group A Streptococcus 4 UI (3-5) ↑	Serratia spp. 1 UI (1-1) ↑
	Enterococcus faecalis 11 UI (8-13) ↑	Group B Streptococcus 4 UI (3-5) ↑	Proteus spp. 1 UI (0-1) ↑

Annualized rate of change (1990-2021) <-3% -3% to -1.5% -1.5% to 0% 0% to 1.5% 1.5% to 3% 3% to 5% >5.0%


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

	Associated	Attributable
Burden Rank	Staphylococcus aureus Methicillin 52 UI (33-70) ↑	Staphylococcus aureus Methicillin 13 UI (9-18) ↑
	Escherichia coli Aminopenicillin 34 UI (22-47) ↑	Acinetobacter baumannii Carbapenems 4 UI (2-5) ↑
	Staphylococcus aureus Fluoroquinolones 30 UI (20-39) ↑	Pseudomonas aeruginosa Carbapenems 3 UI (2-5) ↑
	Escherichia coli Fluoroquinolones 28 UI (20-37) ↑	Streptococcus pneumoniae Carbapenems 2 UI (1-3) ↓
	Escherichia coli TMP-SMX 24 UI (18-31) ↑	Escherichia coli Fluoroquinolones 2 UI (1-3) ↑
	Staphylococcus aureus Macrolides 24 UI (16-33) ↑	Acinetobacter baumannii Fluoroquinolones 2 UI (1-2) ↑
	Acinetobacter baumannii Beta-Lactam/Lactamase Inhib. 20 UI (14-25) ↑	Staphylococcus aureus Fluoroquinolones 2 UI (1-3) ↑
	Escherichia coli 3GC 19 UI (13-25) ↑	Escherichia coli 3GC 2 UI (1-3) ↑
	Escherichia coli Beta-Lactam/Lactamase Inhib. 19 UI (13-24) ↑	Escherichia coli Carbapenems 1 UI (1-2) ↑
	Acinetobacter baumannii 4GC 18 UI (13-24) ↑	Enterococcus faecium Vancomycin 1 UI (1-2) ↑

Annualized rate of change (1990-2021) <-3% -3% to -1.5% -1.5% to 0% 0% to 1.5% 1.5% to 3% 3% to 5% >5.0%

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) bloodstream infections (226 UI (173-279)), lower respiratory infection (excl. COVID) (141 UI (108-173)), peritoneal and intra-abdominal infections (55 UI (39-71)), infections of the skin and subcutaneous systems (33 UI (24-42)) and tuberculosis (24 UI (16-32)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Qatar, people aged under 5 experienced the largest number of deaths associated with AMR in 1990 but this changed by 2021 as the largest number of deaths occurred among the 50 to 69. This indicates that prevention of infections among the under 5 has contributed to the reduction in the number of AMR associated deaths. In 2021, the number of deaths associated with AMR among the 50 to 69 was 78 UI (52-104), whereas the mortality rate per 100,000 was 335 UI (251-419).

Data sources for Qatar

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Qatar by source type

Source type	Years	Sample size	Sample size units
Microbial or laboratory data without outcome	2010-2021	23,166	Isolates
Literature studies	1990-2009	171	Cases/isolates/susceptibility tests
Single drug resistance profile data	2010-2021	142,480	Antibiotic susceptibility test

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care’s Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>